Novel Computational Approaches to Parkinson's Disease Drug Development

Chief Executive Officer

Aug 18, 2021PTV-08-21-CL-002

Drug Discovery and Development PA TV (video)

In this episode, Gain Therapeutics CEO Eric Richman discusses some of the challenges facing drug developers targeting Parkinson's disease and the novel computational approach Gain is taking to serve this unmet medical need.

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-07-26-PA-11Jul 22, 2026

AI-Optimized CLD

From Screening to Design: Can Production Cell Lines Become Programmable Platforms?

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-19Jul 20, 2026

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

PAO-07-26-PA-10Jul 16, 2026

Drug Delivery

Intracellular Delivery: Reaching Targets Beyond the Cell Surface

David Alvaro, Ph.D.

Pharma's Almanac

PAO-07-26-PA-07Jul 14, 2026

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac

PAO-07-26-PA-05Jul 8, 2026

Next-Gen Delivery

Beyond Lipid Nanoparticles: The Search for Next-Generation Delivery Platforms

Pharma's Almanac

PAO-07-26-PA-06Jul 6, 2026

Protein Conformation

Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-17Jul 6, 2026

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

PAO-06-26-CL-04Jul 1, 2026

LAIs

The Long View: How Extended-Duration Therapies Are Reshaping Patient Care

Pharma's Almanac

PAO-07-26-PA-01Jul 1, 2026

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-16Jun 29, 2026

Microbiome Editing

Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-15Jun 22, 2026

CNS Clinical

Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969

Insilico Medicine

PR-06-26-01Jun 17, 2026

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us Nice Insight That's Nice

Reach Our Team

My Account

Subscribe for the newsletter

Subscribe for the Newsletter

Mobile Navigation

Novel Computational Approaches to Parkinson's Disease Drug Development

Related Content

Stem Cells

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

AI-Optimized CLD

From Screening to Design: Can Production Cell Lines Become Programmable Platforms?

David Alvaro, Ph.D.

Pharma's Almanac

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

Drug Delivery

Intracellular Delivery: Reaching Targets Beyond the Cell Surface

David Alvaro, Ph.D.

Pharma's Almanac

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac

Next-Gen Delivery

Beyond Lipid Nanoparticles: The Search for Next-Generation Delivery Platforms

Pharma's Almanac

Protein Conformation

Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.

Samsung Biologics

LAIs

The Long View: How Extended-Duration Therapies Are Reshaping Patient Care

Pharma's Almanac

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

Microbiome Editing

Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies

David Alvaro, Ph.D.

Pharma's Almanac

CNS Clinical

Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969

Insilico Medicine

Related Content

Stem Cells

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

AI-Optimized CLD

From Screening to Design: Can Production Cell Lines Become Programmable Platforms?

David Alvaro, Ph.D.

Pharma's Almanac

Rare Cancer CGT

Developing Cell and Gene Therapies for Rare Oncology Applications

David Alvaro, Ph.D.

Pharma's Almanac

Drug Delivery

Intracellular Delivery: Reaching Targets Beyond the Cell Surface

David Alvaro, Ph.D.

Pharma's Almanac

Tumor-Agnostic

Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology

David Alvaro, Ph.D.

Pharma's Almanac

Next-Gen Delivery

Beyond Lipid Nanoparticles: The Search for Next-Generation Delivery Platforms

Pharma's Almanac

Protein Conformation

Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

Data-Centric Organoid Services for Predictive Drug Response and Next-Generation Oncology Research

Seahee Kim, Ph.D.